Statistical analysis

Adams KF, Jr. Post hoc subgroup analysis and the truth of a clinical trial. Am Heart J 1998; 136(5):753-758.
PMID: 9812066

Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319(7223):1492-1495.
PMID: 10582940

Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317(7168):1309-1312.
PMID: 9804726

Amit O, Heiberger RM, Lane PW. Graphical approaches to the analysis of safety data from clinical trials. Pharm Stat 2008; 7(1):20-35.
PMID: 17323410

Bailar JC, III, Mosteller F. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. Ann Intern Med 1988; 108(2):266-273.
PMID: 3341656

Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schunemann HJ, Tornetta P, III. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res 2006; 447:247-251.
PMID: 16672904 [New]

Bland JM. Quoting intermediate analyses can only mislead. BMJ 1997; 314(7098):1907-1908.
PMID: 9224157

Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310(6977):452-454.
PMID: 7873954

Dongsheng T, Shalay K, Pater J. Adjustment of treatment effects for covariates in clinical trials: statistical and regulatory issues. Drug Information Journal 2000; 34:511-523. Duncan BW, Olkin I. Bias of estimates of the number needed to treat. Stat Med 2005; 24(12):1837-1848.
PMID: 15806616

Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002; 2:8.
PMID: 12069695

Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986; 292(6522):746-750.
PMID: 3082422

Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA. Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005; 9(7):1-iv.
PMID: 15763038

Hernandez AV, Boersma E, Murray GD, Habbema JD, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? Am Heart J 2006; 151(2):257-264.
PMID: 16442886

Julien M, Hanley JA. Profile-specific survival estimates: Making reports of clinical trials more patient-relevant. Clin Trials 2008; 5(2):107-115.
PMID: 18375648

Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 2008; 26(22):3721-3726.
PMID: 18669458

Moreira ED, Jr., Stein Z, Susser E. Reporting on methods of subgroup analysis in clinical trials: a survey of four scientific journals. Braz J Med Biol Res 2001; 34(11):1441-1446.
PMID: 11668354

Murray DM, Pals SL, Blitstein JL, Alfano CM, Lehman J. Design and analysis of group-randomized trials in cancer: a review of current practices. J Natl Cancer Inst 2008; 100(7):483-491.
PMID: 18364501

Newcombe RG. Confidence intervals for the number needed to treat. Absolute risk reduction is less likely to be misunderstood. BMJ 1999; 318(7200):1765-1767.
PMID: 10428570

Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 2002; 287(21):2813-2814.
PMID: 12038920

Pocock SJ, Hughes MD. Estimation issues in clinical trials and overviews. Stat Med 1990; 9(6):657-671.
PMID: 2145623

Pocock SJ, Travison TG, Wruck LM. Figures in clinical trial reports: current practice and scope for improvement. Trials 2007; 8(1):36.
PMID: 18021449

Pocock SJ, Collier TJ, Dandreo KJ, de Stavola BL, Goldman MB, Kalish LA, Kasten LE, McCormack VA. Issues in the reporting of epidemiological studies: a survey of recent practice. BMJ 2004; 329(7471):883.
PMID: 15469946

Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med 1987; 317(7):426-432.
PMID: 3614286

Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365(9454):176-186.
PMID: 15639301

Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet 2005; 365(9471):1657-1661.
PMID: 15885299

Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ 2006; 333(7581):1248.
PMID: 17060338

Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977; 198(4318):679-684.
PMID: 333584

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357(21):2189-2194.
PMID: 18032770

Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 2001; 142(3):502-511.
PMID: 11526365

Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266(1):93-98.
PMID: 2046134

Page last edited: 23 March 2010